CMS

OMNIVISION Launches Industry’s First and Only Image Sensor with TheiaCel™ Technology for Best-In-Class HDR in High-end Smartphones

Retrieved on: 
Monday, March 18, 2024
Semiconductor, Hardware, Audio, Video, Mobile, Wireless, Technology, Smartphone, MP, Original equipment manufacturer, QPD, HDR, Bayer, System, Lighting, Multimedia, PDAF, CMS, Camera

OMNIVISION, a leading global developer of semiconductor solutions , including advanced digital imaging, analog, and touch & display technology , today launched its new OV50K40, the first smartphone image sensor with TheiaCel™ technology.

Key Points: 
  • OMNIVISION, a leading global developer of semiconductor solutions , including advanced digital imaging, analog, and touch & display technology , today launched its new OV50K40, the first smartphone image sensor with TheiaCel™ technology.
  • View the full release here: https://www.businesswire.com/news/home/20240318521456/en/
    OV50K40 - 50MP Smartphone Sensor TheiaCel™ Technology Enables Best-in-class Single-exposure HDR (Graphic: Business Wire)
    OMNIVISION’s new TheiaCel™ technology harnesses the capabilities of lateral overflow integration capacitors (LOFIC) to provide the best-in-class single-exposure HDR, regardless of lighting conditions.
  • But today, OMNIVISION has disrupted the mobile phone industry with our new TheiaCel™ technology,” said Arun Jayaseelan, senior product marketing manager, OMNIVISION.
  • We look forward to applying the TheiaCel™ technology to additional mobile image sensors as well as new markets in the future.

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.

Edifecs to Speak at RISE National 2024

Retrieved on: 
Friday, March 15, 2024
Software, Internet, General Health, Health, Artificial Intelligence, Data Management, Technology, Health Insurance, Diagnosis, Organization, EDI, FHIR, Risk, Health information management, AI, APM, Fraud, API, Alignment, Artificial intelligence, EHR, Medicare, CMS, Government

Edifecs, Inc. , a global health information technology solutions company, is moderating a panel discussion at the RISE National 2024 conference, March 17-19, 2024, in Nashville, Tennessee.

Key Points: 
  • Edifecs, Inc. , a global health information technology solutions company, is moderating a panel discussion at the RISE National 2024 conference, March 17-19, 2024, in Nashville, Tennessee.
  • At the same time, the government is actively investigating upcoding and overpayments, as well as addressing allegations of fraud.
  • To traverse this tightrope, both health plans and providers need the right technological capabilities to realize improvements in care, quality, and cost.
  • During the event, Edifecs will showcase solutions that allow plans and providers alike to accelerate value-based payment adoption, more accurately manage population risk, and ensure adequate care funding.

Humana Completes Aggregate $2.25 Billion Debt Offering

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Other Professional Services, Insurance, Health Insurance, Managed Care, General Health, Failure, Administration, Growth, Goldman Sachs, Inc., Final, Wells Fargo, Form, Risk, Star, Morgan Stanley, Information, Sale, News, Security (finance), Judgement, Prospectus, Service, Note, Pharmacy, Debt-to-GDP ratio, Medicare, Privacy, CMS, Government, Risk management

Humana Inc. (the “company”) (NYSE: HUM) announced today the completion of its public offering of $2.25 billion in aggregate principal amount of senior notes.

Key Points: 
  • Humana Inc. (the “company”) (NYSE: HUM) announced today the completion of its public offering of $2.25 billion in aggregate principal amount of senior notes.
  • The company expects net proceeds from the Senior Notes Offerings will be approximately $2.226 billion after deducting underwriters’ discounts and estimated offering expenses.
  • This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

Quantum Health Announces New Navigation Service to Support Medicare Advantage Market

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Insurance, Health Insurance, Managed Care, General Health, HOS, RTI, Pressure, Communication, PCP, Health care, Multimedia, Medicare, CMS, Medicare Advantage, Uday Chopra, Health insurance

Quantum Health , the leading consumer healthcare navigation and care coordination company, today announced it has launched a new navigation service to support Medicare Advantage plans as they look to enhance member experience and retention to help improve plans’ Star Ratings, close gaps in care and drive better clinical outcomes.

Key Points: 
  • Quantum Health , the leading consumer healthcare navigation and care coordination company, today announced it has launched a new navigation service to support Medicare Advantage plans as they look to enhance member experience and retention to help improve plans’ Star Ratings, close gaps in care and drive better clinical outcomes.
  • By helping Medicare Advantage members effectively navigate their care benefits and manage provider interactions, members get ongoing support, better and more appropriate care, and improved outcomes.
  • Key components of Quantum Health’s Medicare Advantage service offering:
    Improved member engagement and experience: Quantum Health will support members with a team of dedicated experts that provide proactive member support, along with helping Medicare Advantage plans comply with CMS requirements, conducting annual health risk assessments, confirming primary care physician (PCP) assignment, and helping members access needed care to proactively close care gaps and document future care needs.
  • “We have designed our Medicare Advantage navigation service to meet the unique needs of both Medicare Advantage plans and their member populations.

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

Retrieved on: 
Tuesday, March 12, 2024
Health, Hospitals, Neurology, Health Technology, Practice Management, Physical Therapy, HCPCS, Durable medical equipment, Brain, BCI, Patient, DME, Stroke, Classification, Survivor, Medicare, FDA, CMS, Movement, Rehabilitation, Medical device

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

Key Points: 
  • E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.
  • The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits.
  • CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME).
  • Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation.

Performant Financial Corporation Announces Financial Results for Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 12, 2024
Payments, Health, Technology, Health Technology, Practice Management, General Health, Customer service, Growth, Telephone, Health care, Bank statement, Investment, Medicaid, Depreciation, GAAP, ID, CMS, Total, Pharmaceutical industry

Revenues from Customer Care / Outsourced Services in the fourth quarter were $1.4 million, compared to $3.1 million in the prior year period.

Key Points: 
  • Revenues from Customer Care / Outsourced Services in the fourth quarter were $1.4 million, compared to $3.1 million in the prior year period.
  • Adjusted EBITDA for the fourth quarter was $4.5 million compared to $2.3 million in the prior year period.
  • Revenues for the full year ended December 31, 2023 were $113.7 million, compared to revenues of $109.2 million in the prior year.
  • The Company will hold a conference call to discuss its fourth quarter and full year 2023 results today at 5:00 p.m. Eastern.

Humana Prices $2.25 Billion Debt Offering

Retrieved on: 
Tuesday, March 12, 2024
Professional Services, Health, Other Professional Services, Insurance, Health Insurance, Managed Care, General Health, Failure, Administration, Growth, Goldman Sachs, Inc., Final, Wells Fargo, Form, Risk, Star, Morgan Stanley, Information, Sale, News, Security (finance), Judgement, Prospectus, Service, Note, Pharmacy, Debt-to-GDP ratio, Medicare, Privacy, CMS, Government, Risk management

Humana Inc. (the “company”) (NYSE: HUM) announced today that it has priced a public offering of $2.25 billion in aggregate principal amount of senior notes.

Key Points: 
  • Humana Inc. (the “company”) (NYSE: HUM) announced today that it has priced a public offering of $2.25 billion in aggregate principal amount of senior notes.
  • The company expects net proceeds from the Senior Notes Offerings will be approximately $2.226 billion after deducting underwriters’ discounts and estimated offering expenses.
  • This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, FDA, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Conference, CKD, CANF, Business development, Inflammation, Pancreatic cancer, Drug development, Liver cancer, CMS, Pharmaceutical industry

Can-Fite’s pipeline of indications includes Namodenoson for the treatment of advanced liver cancer and pancreatic cancer; both indications have been licensed to the Swiss company Ewopharma for Eastern Europe.

Key Points: 
  • Can-Fite’s pipeline of indications includes Namodenoson for the treatment of advanced liver cancer and pancreatic cancer; both indications have been licensed to the Swiss company Ewopharma for Eastern Europe.
  • The liver cancer indication has been licensed as well to CMS in China and CKD in South Korea.
  • Piclidenoson has been out-licensed to Cipher in Canada; Gebro Pharma for Swiss, Spain, Austria; CMS for China; and Kyongboo for South Korea.
  • “Advanced liver cancer and pancreatic cancer are Can-Fite’s clinical-stage indications for Namodenoson and am delighted with the interest that Namodenoson is raising with companies that will participate in the Bio Europe Conference and are experts in drug development and distribution in the oncology arena.

Best’s Commentary: Narrowing Margins in Medicare Advantage Segment Could Hinder Health Insurer Profitability Levels

Retrieved on: 
Monday, March 11, 2024
Insurance, Professional Services, Growth, ALL, News, AM Best, Medicare, CMS, Medicare Advantage, Ageing, Pharmaceutical industry

The impact of higher than expected utilization levels for Medicare Advantage (MA) products could lead to a deterioration in profitability and adversely impact health insurers’ overall financial results, according to a new AM Best commentary.

Key Points: 
  • The impact of higher than expected utilization levels for Medicare Advantage (MA) products could lead to a deterioration in profitability and adversely impact health insurers’ overall financial results, according to a new AM Best commentary.
  • The Best’s Commentary, “Narrowing Margins in Medicare Advantage,” states that higher utilization levels reported by several companies in fourth-quarter 2023 may not have been anticipated fully in filings pertaining to 2024 rates.
  • In addition, an initial notice from The Centers for Medicare and Medicaid Services for 2025 rate levels is significantly below prior years.
  • The commentary also raises the issue of whether the elevated utilization trends in 2023 were adequately captured into pricing for 2024.